OPTN - OptiNose, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.35
+0.71 (+8.28%)
At close: 4:00PM EST

9.35 0.00 (0.00%)
After hours: 5:26PM EST

Stock chart is not supported by your current browser
Previous Close8.64
Open8.74
Bid8.63 x 1800
Ask9.53 x 1000
Day's Range8.60 - 9.38
52 Week Range4.44 - 11.66
Volume198,874
Avg. Volume280,112
Market Cap389M
Beta (3Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference

    YARDLEY, Pa., Nov. 26, 2019 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today.

  • GlobeNewswire

    Optinose Announces Pricing of Public Offering of Common Stock

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $9.75 per share, before underwriting discounts. The offering consists of 4,250,000 shares being sold by Optinose and 1,250,000 shares being sold by certain selling stockholders, resulting in aggregate net proceeds of approximately $39.0 million to Optinose and approximately $11.5 million to the selling stockholders, after deducting underwriting discounts and before offering expenses. In addition, Optinose and the selling stockholders have granted the underwriters an option for a period of 30 days to purchase up to an additional 825,000 shares at the public offering price, less the underwriting discount.

  • GlobeNewswire

    Optinose Announces Proposed Public Offering of Common Stock

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it and certain selling stockholders intend to offer and sell shares of its common stock in an underwritten public offering. In addition, Optinose is expected to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the total number of shares to be offered at the public offering price, less the underwriting discount. Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes.

  • GlobeNewswire

    Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects.

  • GlobeNewswire

    Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2019, after market close on Tuesday, November 12, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • GlobeNewswire

    Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

    YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) --  Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new role of Vice President, Business Development and appointment of Michael Richardson into the new position. In this role, Michael will be responsible for identifying, evaluating, and executing on business development opportunities that support the overall corporate strategy.

  • GlobeNewswire

    Optinose to Present at the 2019 Cantor Global Healthcare Conference

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2019 Cantor Global Healthcare Conference on October 2, 2019, at 11:15 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

  • PR Newswire

    Currax™ Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®

    Currax's first acquisition comes fewer than five months after the company's founding in April of 2019 The acquisition of ONZETRA® Xsail® bolsters Currax's Branded products portfolio MORRISTOWN, N.J. , ...

  • GlobeNewswire

    OptiNose Announces License Agreement Related to ONZETRA XSAIL

    OptiNose, Inc. (Optinose) (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement between its Norway-based subsidiary OptiNose AS and Currax Pharmaceuticals LLC (Currax) which grants Currax the exclusive rights to certain Optinose intellectual property for the purpose of marketing ONZETRA® XSAIL® (sumatriptan nasal powder) in the United States, Canada, and Mexico. Under the terms of the License Agreement, Currax is required to pay a $4.48 million upfront payment, of which $750,000 shall be held in escrow for a limited period to cover certain indemnification obligations.

  • GlobeNewswire

    Optinose Announces Departure of Chief Commercial Officer

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the departure of its Chief Commercial Officer, Tom Gibbs. Mr. Gibbs will be leaving the Company next week to assume a senior general management role at a major multinational pharmaceutical company. Senior members of the Optinose commercial leadership, including Vice Presidents of sales, marketing, and market access, will report directly to Optinose President and Chief Operating Officer Ramy Mahmoud on an interim basis as the Company initiates a search for a Chief Commercial Officer.

  • GlobeNewswire

    Optinose Announces $150 Million Debt Financing from Pharmakon

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported that it has entered into a note purchase agreement for up to $150 million of senior secured notes with funds managed by Pharmakon Advisors, LP (“Pharmakon”), the investment manager of the BioPharma Credit funds. “The capital available under this facility has the potential to meaningfully extend our cash runway, and Pharmakon’s reputation of forming successful, long-term, relationships with growth-stage companies such as Optinose makes them a great financial partner for us,” commented Chief Financial Officer Keith Goldan.

  • GlobeNewswire

    Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

    XHANCE net revenue grew 68% to $6.7 million from first to second quarter 2019 XHANCE prescriptions increased 51% from first to second quarter 2019 Company expects XHANCE net.

  • ACCESSWIRE

    OptiNose, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 12, 2019 / OptiNose, Inc. (NASDAQ: OPTN) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 at 4:30 PM Eastern ...

  • GlobeNewswire

    Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the second quarter 2019, after market close on Monday, August 12, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • GlobeNewswire

    Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2019 BMO Capital Markets Prescriptions for Success Healthcare Conference on June 25, 2019, at 9:40 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

  • GlobeNewswire

    Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2019 in the medium-sized company category. “From the very start of Optinose in 2010, we believed that hiring great people and creating a work environment in which those people can come together and accomplish even greater things together should be our highest priority,” said Peter Miller, CEO of Optinose. “Receiving public recognition of Optinose as a ‘Best Place to Work’ is an honor, and it is only possible because of the quality and commitment of our colleagues,” added Ramy Mahmoud, MD, President and Chief Operating Officer of Optinose.

  • GlobeNewswire

    Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2019, and provided recent operational highlights. At the same time, the Company completed its transition from a contract sales force model to an internal sales force model.

  • GlobeNewswire

    Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2019, before market open on Thursday, May 9, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • GlobeNewswire

     Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights

    Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million XHANCE prescriptions increased 50 percent from Q3 to Q4 of 2018.

  • GlobeNewswire

    Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter 2018, before market open on Wednesday, March 6, 2019. Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com.

  • GlobeNewswire

    Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the United States Patent and Trademark Office (USPTO) recently issued four patents covering XHANCE® (fluticasone propionate) nasal spray. “We are pleased to further strengthen our intellectual property portfolio with the  addition of these patents.

  • GlobeNewswire

    Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco

    YARDLEY, Pa., Feb. 15, 2019 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today.

  • GlobeNewswire

    Optinose Announces License Agreement

    Optinose (OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a license agreement with Inexia whereby Inexia has obtained certain rights that will enable the use of Optinose’s Exhalation Delivery Systems (EDS) and other intellectual property in their effort to discover and develop novel therapies based on positive modulators of Orexin OX1 and OX2 for neurological diseases.

  • GlobeNewswire

    Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL  

    Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate the License Agreement to develop and commercialize ONZETRA® XSAIL® in the United States, Canada, and Mexico. Upon termination of the license agreement, Optinose may elect to continue to commercialize ONZETRA XSAIL itself or through a new licensee. “Optinose intends to evaluate its options with respect to the future of ONZETRA XSAIL,” stated CEO Peter Miller.